Stage III Pancreatic Cancer AJCC v8 Clinical Trials

15 studies are recruiting for stage iii pancreatic cancer ajcc v8 in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Portland, Oregon 6 Chicago, Illinois 5 Lexington, Kentucky 5 Sacramento, California 5 Atlanta, Georgia 4 New Haven, Connecticut 4 Pittsburgh, Pennsylvania 4 Baltimore, Maryland 3 Buffalo, New York 3 Cincinnati, Ohio 3 Columbus, Ohio 3 Des Moines, Iowa 3 Detroit, Michigan 3 Duarte, California 3 Fargo, North Dakota 3 Gainesville, Florida 3 Green Bay, Wisconsin 3 Houston, Texas 3 Irvine, California 3 Kansas City, Kansas 3 Madison, Wisconsin 3 Memphis, Tennessee 3 New York, New York 3 Omaha, Nebraska 3 Orange, California 3 Phoenix, Arizona 3 Richmond, Virginia 3 San Francisco, California 3 Seattle, Washington 3 St Louis, Missouri 3 Washington D.C., District of Columbia 3 Wilmington, Delaware 3

Studies now recruiting

  1. Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

    This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment of pancreatic ductal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Yale University Cancer Center LAO, New Haven, Connecticut
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07619521 on ClinicalTrials.gov

  2. Targeted Pathway Inhibition in Patients With Pancreatic Cancer

    This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pr…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    OHSU Knight Cancer Institute, Portland, Oregon
    Run by
    OHSU Knight Cancer Institute

    See if you can join NCT04005690 on ClinicalTrials.gov

  3. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope Comprehensive Cancer Center, Duarte, California
    Locations
    18 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05372614 on ClinicalTrials.gov

  4. Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

    This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor ce…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope Comprehensive Cancer Center, Duarte, California
    Locations
    44 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04172532 on ClinicalTrials.gov

  5. Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

    This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care options include additional chemotherapy, observation, or sta…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Banner MD Anderson Cancer Center, Gilbert, Arizona
    Locations
    333 in total
    Run by
    NRG Oncology

    See if you can join NCT06958328 on ClinicalTrials.gov

  6. AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

    This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be removed by surgery (borderline resectable), that has spread to nearby tiss…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
    Run by
    Jonsson Comprehensive Cancer Center

    See if you can join NCT07619313 on ClinicalTrials.gov

  7. TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

    This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), that cannot be removed by surgery (unresectable), that has spread from…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California Davis Comprehensive Cancer Center, Sacramento, California
    Run by
    University of California, Davis

    See if you can join NCT07189195 on ClinicalTrials.gov

  8. Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

    This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Entinostat is in a class of drugs called histone deacetylase …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Yale University, New Haven, Connecticut
    Locations
    3 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05053971 on ClinicalTrials.gov

  9. A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy

    This clinical trial studies whether a tailored, web-based program (web portal), Community for Physical Activity and Supportive Nutrition Strategies (COMPASS), can be used to improve exercise and dietary changes in patients with stage I-III pancreatic cancer who are receiving chemotherapy before sur…

    Stage
    Not phased
    Ages
    18 and older
    Site
    OHSU Knight Cancer Institute, Portland, Oregon
    Run by
    OHSU Knight Cancer Institute

    See if you can join NCT07651358 on ClinicalTrials.gov

  10. Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

    This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Anchorage Associates in Radiation Medicine, Anchorage, Alaska
    Locations
    274 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT06998940 on ClinicalTrials.gov

  11. Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

    This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resect…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
    Run by
    Emory University

    See if you can join NCT06423326 on ClinicalTrials.gov

  12. Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

    This phase Ib trial tests the safety, side effects, and best dose of leflunomide in combination with gemcitabine in treating patients with pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cannot be removed …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    City of Hope Medical Center, Duarte, California
    Run by
    City of Hope Medical Center

    See if you can join NCT06454383 on ClinicalTrials.gov

  13. OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

    This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). OMO-103 ma…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    OHSU Knight Cancer Institute, Portland, Oregon
    Run by
    OHSU Knight Cancer Institute

    See if you can join NCT07089940 on ClinicalTrials.gov

  14. A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

    This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in the bod…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University-Telemedicine, Birmingham, Alabama
    Locations
    109 in total
    Run by
    Sameek Roychowdhury

    See if you can join NCT06906562 on ClinicalTrials.gov

  15. CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

    This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Northwestern University, Chicago, Illinois
    Run by
    Northwestern University

    See if you can join NCT05733000 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.